Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets

  Merck to Present New Data Analyses of its Investigational Ragweed Pollen and
  Grass Pollen Allergy Immunotherapy Tablets

Business Wire

WHITEHOUSE STATION, N.J. -- February 22, 2013

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
announced that researchers will present new data analyses of the safety and
efficacy of the company’s investigational allergy immunotherapy tablets (AITs)
for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum
pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI)
Annual Meeting. The meeting will be held in San Antonio from February 22-26.

Merck's AIT products are investigational, dissolvable oral tablets designed to
help treat the underlying cause of allergic rhinitis by generating an immune
response to help protect against targeted allergens. Merck has partnered with
ALK-Abello to develop AITs in North America. Earlier this year, Merck
submitted a Biologics License Application (BLA) for its grass pollen AIT to
the U.S. Food and Drug Administration (FDA), and Merck plans to submit a BLA
for its ragweed pollen AIT to the FDA later in 2013.

“We are pleased to present new results for Merck’s investigational AIT
products to the scientific community that we believe will be valuable in
thinking about immunotherapy and the treatment of allergic rhinitis,” said
Jeffrey A. Chodakewitz, M.D., senior vice president, Global Scientific
Strategy, franchise head, Infectious Diseases and interim franchise head,
Respiratory & Immunology, Merck Research Laboratories. “Merck is committed to
research in the area of allergic rhinitis.”

Select Merck Presentations at AAAAI

Sunday, Feb. 24, 2013 9:45 a.m.-10:45 a.m., Poster Session 3209, Exhibit Hall

  *403: Characterizing the 12 Amb a 1-U Ragweed Allergy Immunotherapy Tablet
    Adverse Event Profile in Adults with Ragweed-Induced Allergic
  *405: Safety of Ragweed Allergy Immunotherapy Tablet: Results From Four
    Placebo-Controlled Trials

Tuesday, Feb. 26, 2013 9:45 a.m.-10:45 a.m., Poster Session 5206, Exhibit Hall

  *809: Ragweed Allergy Immunotherapy Tablet Reduces Use of Ocular
    Antihistamines in Patients With Ragweed Pollen–Induced Allergic
  *810: Effect of Allergy Immunotherapy Tablet in Patients with or without
    Local Application-Site Reactions

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline products
that the products will receive the necessary regulatory approvals or that they
will prove to be commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site


Pam Eisele, 908-423-5042
Lesley Brown, 267-305-3545
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088
Press spacebar to pause and continue. Press esc to stop.